Prevent the Preventable

Patient safety is the utmost importance to you. We understand. It is for us too. Quantitative Neuromuscular Blockade Monitoring augments your clinical expertise and provides unwavering confidence in clinical decision making from start to finish.

Senzime´s innovative device, TetraGraph®, supports the optimization of patient management in patients receiving neuromuscular blocking agents (NMBAs). TetraGraph® can be used from start to finish during the surgical procedure. The monitor enables objective assessment of the depth of block and titration of medication dosage to help determine when the patient has recovered sufficiently to maintain spontaneous breathing.

Senzime, Inc. is located in Naples, Florida.

Residual Neuromuscular Blockade

Qualitative vs Quantitative Monitoring

EMG

The new Gold Standard

Press releases

CEO Pia Renaudin buys shares for SEK 5.5 million in Senzime

Read more

Communique from extra general meeting in Senzime AB (publ)

Read more

Senzime expands US sales team and signs additional distribution agreements

Read more
See all »

News

Senzime invitation to new website

Read more

Senzime Joins the Anesthesia Patient Safety Foundation (APSF) as a member of the Corporate Advisory Counsel

Read more

The latest evidence in the Management of Neuromuscular Blockade

Read more
See all »